Phase II multi-arm, randomised open label trial of Lutetium-177 Octreotate peptide receptor radionucleotide therapy, capecitabine/temozolamide chemotherapy, or the combination in the first or second line treatment of low to intermediate grade gastroenteropancreatic neuroendocrine tumours